Geographic balance will continue to shift toward pharmerging
countries, which are expected to grow at a 14-17% rate through 2014,
while major developed markets will grow at 3-6%. The US will remain the
single largest market in the world with revenue just short of $400
million by 2014 while China will grow to become the world’s 3rd largest
market for pharmaceuticals during this period.
Therapy area growth will continue to be driven by innovation and areas of unmet need. In the areas of oncology, diabetes, multiple sclerosis and HIV, annual growth is expected to exceed 10% as new drugs are brought to market, patient access is expanded and funding is redirected from other areas where lower cost generics will be available.
Broad cuts in spending will be applied by public payers to publicreduce growth in drug budgets. Publicly funded health systems are under increased pressure to reduce growth in drug budgets following the global economic downturn. Governments seeking to restore fiscal balance will likely apply restrictions or reductions in reimbursements to reduce drug spending.
Peak years of patent expiries will shift major therapies to generic dominance. Products with over $140 billion in revenue will face generic competition in the next five years with therapy areas like cholesterol regulators, antipsychotics and anti-ulcerants being affected the most.
Closer scrutiny of new products will keep product launches in the range of 30-35 products annually but these products will be subjected to more rigorous and complex assessments by payers before being accepted into clinical practice and reimbursed.
In moving beyond 2014 and leading up to 2020, IMS expects to see a continuing shift toward biopharmaceuticals, specialty-driven products and changes in the mix of disease areas of interest.
Discovery Search Partners has an outstanding performance record in pharmaceuticals, biopharmaceuticals and specialty pharmaceuticals. We have proven expertise across all functional areas, with possibly the deepest experience in R&D where innovation is the critical ingredient driving company success. Additionally, we have broad therapy experience and can cite numerous placements of note in virtually all therapy areas of interest.
Therapy area growth will continue to be driven by innovation and areas of unmet need. In the areas of oncology, diabetes, multiple sclerosis and HIV, annual growth is expected to exceed 10% as new drugs are brought to market, patient access is expanded and funding is redirected from other areas where lower cost generics will be available.
Broad cuts in spending will be applied by public payers to publicreduce growth in drug budgets. Publicly funded health systems are under increased pressure to reduce growth in drug budgets following the global economic downturn. Governments seeking to restore fiscal balance will likely apply restrictions or reductions in reimbursements to reduce drug spending.
Peak years of patent expiries will shift major therapies to generic dominance. Products with over $140 billion in revenue will face generic competition in the next five years with therapy areas like cholesterol regulators, antipsychotics and anti-ulcerants being affected the most.
Closer scrutiny of new products will keep product launches in the range of 30-35 products annually but these products will be subjected to more rigorous and complex assessments by payers before being accepted into clinical practice and reimbursed.
In moving beyond 2014 and leading up to 2020, IMS expects to see a continuing shift toward biopharmaceuticals, specialty-driven products and changes in the mix of disease areas of interest.
Discovery Search Partners has an outstanding performance record in pharmaceuticals, biopharmaceuticals and specialty pharmaceuticals. We have proven expertise across all functional areas, with possibly the deepest experience in R&D where innovation is the critical ingredient driving company success. Additionally, we have broad therapy experience and can cite numerous placements of note in virtually all therapy areas of interest.
No comments:
Post a Comment